Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...

Big tech earnings have inspired a substantial rise in Nasdaq futures in overnight trading after the Federal Reserve, led by ...

Owing to Briumvi's solid launch, TG's balance sheet is in excellent condition. Despite new competition, Briumvi's five-year ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma <li /> Designation grante ...

Palo Alto Networks' (PANW) potential acquisition of CyberArk (CYBR) would complement Palo Alto's existing and bolster its ...

CyberArk Software ( NASDAQ: CYBR) soared 13% on a report that Palo Alto Networks ( NASDAQ: PANW) is in discussions to ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...